Month: August 2018

Lexington Announces Non-Brokered Private Placement

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN VANCOUVER, British Columbia, Aug. 27, 2018 — Lexington Biosciences, Inc. (CSE: LNB) (OTCQB: LXGTF) (the “Company” or “Lexington”) announces that it has terminated its agreement with Gravitas Securities Inc. and Canaccord Genuity Corp. in connection with its previously announced brokered private placement (see news releases

Read More

Lexington Announces First Multicenter Clinical Study Site

Company embarks on pivotal clinical study VANCOUVER, British Columbia, Aug. 21, 2018 — Lexington Biosciences, Inc. (CSE: LNB) (OTCQB: LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, is pleased to announce the Medical College of Wisconsin as the first site in its multicenter clinical study for the HeartSentry portable cardiovascular health monitor. “Our

Read More



Newsletter Updates

If you haven’t already done so, signup here to receive future editions and the latest company news direct to your inbox.

Latest News